Indeed, HSP90 inhibitors have been shown to promote AR degradation in prostate cancer cells and synergize with ADT [43], but these compounds are less effective in CRPC driven by AR-Vs signaling, such as in C4–2B MDVR and CWR22Rv1 cells [44,45]. The gene discussed is AR; the disease is prostate cancer.